

Brain dysfunction in sepsis

Romain Sonnevile, M.D., Ph.D.

Médecine Intensive Réanimation

Hôpital Bichat Claude Bernard, AHP, Paris

INSERM U1148, Université Paris Diderot

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Keywords: adolescents; self-esteem; social support; coping strategies; family functioning

Box 3. New Terms and Definitions

- Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
- Organ dysfunction can be identified as an acute change in total SOFA score ≥ 2 points consequent to the infection.

Table 1. Sequential [Sepsis-Related] Organ Failure Assessment Score^a

| System | Score | | | | |
|--|-------|---|---|------|------|
| | 0 | 1 | 2 | 3 | 4 |
| Respiration | | | | | |
| <ul style="list-style-type: none"> • A SOFA score ≥ 2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted. | | | | | |
| ($\mu\text{mol/L}$) | | | | | |
| Urine output, mL/d | | | | <500 | <200 |

Abbreviations: FiO_2 , fraction of inspired oxygen; MAP, mean arterial pressure; PaO_2 , partial pressure of oxygen.

^a Adapted from Vincent et al.²⁷

^b Catecholamine doses are given as $\mu\text{g/kg/min}$ for at least 1 hour.

^c Glasgow Coma Scale scores range from 3-15; higher score indicates better neurological function.

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Angus DC, et al. JAMA. 2018;323(3):e179711. doi:10.1001/jama.2018.0293. PMID: 30102328

- Patients with suspected infection who are likely to have a prolonged ICU stay or to die in the hospital can be promptly identified at the bedside with qSOFA, ie, alteration in mental status, systolic blood pressure ≤ 100 mm Hg, or respiratory rate ≥ 22 /min.

Box 4. qSOFA (Quick SOFA) Criteria

Respiratory rate ≥ 22 /min

Altered mentation

Systolic blood pressure ≤ 100 mm Hg

Brain dysfunction in sepsis

- **Definitions**
- Risk factors and outcomes
- Is clinical evaluation feasible ?
- Does EEG help ?
- Biomarkers ?
- When should we perform brain MRI ?
- Major confounders
- Conclusion

Sepsis-associated encephalopathy

Teneille E. Gofton and G. Bryan Young

Diffuse cerebral dysfunction that accompanies sepsis, **in the absence of direct CNS infection**

Early feature of infection and might appear **before other systemic features of sepsis.**

Many synonyms have been used in the literature to describe the same entity (encephalopathy, brain dysfunction....)

At sepsis onset, many patients with **SAE** usually meet diagnostic criteria for **delirium or coma**


The Spectrum of Septic Encephalopathy

Definitions, Etiologies, and Mortalities

Leorio A. Eidelman, MD; Debby Futterman, MD; Chaim Futterman, MD; Charles L. Sprung, MD

N=50 non-sedated patients with severe sepsis / septic shock

Septic encephalopathy, as defined by a GCS < 15 : **27 (54%) patients**



Potentially modifiable factors contributing to sepsis-associated encephalopathy

Romain Sonnevile^{1,2}, Ltienne de Montmollin^{3,4}, Julien Roujard⁵, Maïté Garrouste-Orges^{2,6}, Bertrand Souweine⁶, Michael Damon^{2,6}, Eric Mariotte⁶, Laurent Argaud¹⁰, François Barbier¹¹, Dany Gologran-Isledano¹², Guillaume Marcotte¹³, Anne Sylvie Dumenil¹⁴, Samir Jamal¹⁵, Guillaume Lacave¹⁶, Stéphane Ruckly⁷, Bruno Mourvillat^{1,8} and Jean-François Timsit^{1,9}


Retrospective analysis of a prospective multicenter database
1997-2014, 17 ICUs in France

SAE defined at ICU admission by

- A score on **GCS** < 15

OR

- when **features of delirium** were noted





Brain dysfunction in sepsis


- Definitions
- **Risk factors and outcomes**
- Is clinical evaluation feasible ?
- Does EEG help ?
- Biomarkers ?
- When should we perform brain MRI ?
- Major confounders
- Conclusion

Understanding brain dysfunction in sepsis

Romain Sonnevile^{1,2}, Franck Verdonk², Camille Baturier², Isabelle F Klein³, Michel Wolff¹, Djillali Annane⁴, Fabrice Chretien² and Tarek Sharshar^{2,4*}









Systemic infection and delirium: when cytokines and acetylcholine collide

Willem A van Gool, Diederik van de Beek, Piet Eikelenboom



Impact of Hyperglycemia on Neuropathological Alterations during Critical Illness



Potentially modifiable factors contributing to sepsis-associated encephalopathy

Romain Sonnevile^{1,2}, Ltienne de Montmollin^{3,4}, Julien Roujade¹, Maïté Garrouste-Orgeas^{5,6}, Bertrand Souweine⁶, Michaël Darmon^{5,6}, Eric Mariotte⁷, Laurent Argaud¹⁰, François Barbier¹¹, Dany Gologran-Isledano¹², Guillaume Marcotte¹³, Anne Sylvie Dumenil¹⁴, Samir Jamal¹⁵, Guillaume Lacave¹⁶, Stéphane Ruckly², Bruno Mourvillat^{1,8} and Jean-François Timsit^{1,8}

Risk factors for sepsis-associated encephalopathy, multivariate analysis

| Variable | OR | 95% CI | | p value |
|-------------------------------------|------|--------|------|---------|
| Age, per 1-year increment | 1.02 | 1.01 | 1.02 | <0.01 |
| Chronic alcohol abuse | 3.38 | 2.34 | 4.89 | <0.01 |
| History of neurological disease | 1.56 | 1.18 | 2.06 | <0.01 |
| Pre-existing cognitive impairment | 2.25 | 1.09 | 4.67 | 0.03 |
| Long-term use of psychoactive drugs | 1.37 | 1.11 | 1.70 | <0.01 |
| Medical admission ^a | 1.75 | 1.43 | 2.14 | <0.01 |
| Renal SOFA > 2 | 1.41 | 1.19 | 1.67 | <0.01 |
| Hypoglycemia, <3 mmol/l | 2.66 | 1.27 | 5.59 | <0.01 |
| Hyperglycemia, >10 mmol/l | 1.37 | 1.09 | 1.72 | <0.01 |
| Hypercapnia, >45 mmHg | 1.91 | 1.53 | 2.38 | <0.01 |
| Hypernatremia, >145 mmol/l | 2.30 | 1.48 | 3.57 | <0.01 |

Potentially modifiable factors contributing to sepsis-associated encephalopathy

Romain Sonnevile^{1,2}, Ltienne de Montmollin^{3,4}, Julien Roujade¹, Maïté Garrouste-Orges^{5,6}, Bertrand Souweine⁶, Michael Damon^{5,6}, Eric Mariotte⁶, Laurent Argaud¹⁰, François Barbier¹¹, Dany Gologran-Toledano¹², Guillaume Marcotte¹³, Anne Sylvie Dumenil¹⁴, Samir Jamal¹⁵, Guillaume Lacave¹⁶, Stéphane Ruckly⁷, Bruno Mourvillat^{1,8} and Jean-François Timsit^{1,9}

Short term outcomes

| Variable | No SAE N=1172 | SAE N=1341 | p |
|---------------------------------|------------------|---------------|-------|
| Need for invasive MV, n (%) | 588 (50) | 1039 (78) | <0.01 |
| Need for propofol or BZD, n (%) | 423 (36) | 796 (59) | <0.01 |
| Need for vasopressors, n (%) | 803 (69) | 1067 (80) | <0.01 |
| Need for RRT, n (%) | 231 (20) | 411 (31) | <0.01 |
| Length of ICU stay, days | | | |
| Whole population | 5 (3-12) | 7 (3-15) | <0.01 |
| Survivors (n=1539) | 5 (3-11) | 9 (5-17) | <0.01 |

Data are numbers (percentage) or median (IQR)

Potentially modifiable factors contributing to sepsis-associated encephalopathy

Romain Sonnevile^{1,2}, Etienne de Montmollin³, Julien Roujade¹, Maïté Garrouste-Orgeas^{2,3}, Bertrand Souweine⁴, Michael Damon^{5,6}, Eric Mariotte⁷, Laurent Argaud^{1,8}, François Barbier^{1,1}, Dany Gologran-Toledano^{1,2}, Guillaume Marcotte^{1,2}, Anne-Sylvie Duménil^{1,1}, Samir Jamal^{1,9}, Guillaume Lacave^{1,6}, Stéphane Ruckly², Bruno Mourvillat^{1,3} and Jean-François Timsit^{1,3}


Multivariate analysis of factors associated with mortality (censored at day 30)

| Variable | Adjusted HR* | 95%CI | p |
|----------------------------------|--------------|-----------|--------|
| Sepsis-associated encephalopathy | | | < 0.01 |
| GCS 3-8 | 3.37 | 2.82-4.03 | |
| GCS 9-12 | 1.80 | 1.41-2.29 | |
| GCS 13-14 | 1.38 | 1.09-1.76 | |
| GCS 15, features of delirium | 1.06 | 0.80-1.41 | |
| GCS 15, no feature of delirium | Ref. | | |

**Adjusted for age, chronic immunodepression, chronic cardiac disease, chronic respiratory disease, chronic liver disease, year of admission, and non-neurological SOFA*

Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis

Figure 2. Cognitive Impairment Among Survivors of Severe Sepsis at Each Survey Time Point



Error bars indicate 95% confidence intervals (CIs); IQR, interquartile range.

Interpretive Example: Compared with stable rates before severe sepsis, the prevalence of moderate to severe cognitive impairment increased from 6.1% (95% CI, 4.2%-8.0%) before severe sepsis to 16.7% (95% CI, 13.8%-19.7%) at the first survey after severe sepsis ($P < .001$ by χ^2 test; Table 2).

The Lingering Consequences of Sepsis

A Hidden Public Health Disaster?

SEPSIS



Long term cognitive impairment



Functional dependence

RESEARCH PAPER

Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors

Alexander Semmler,^{1,6} Catherine Nichols Widmann,¹ Thorsten Okulla,¹ Horst Urbach,² Markus Kaiser,^{3,7} Guido Widman,⁴ Florian Mormann,^{4,8} Julia Weide,¹ Klaus Fließbach,⁴ Andreas Hoeft,³ Frank Jessen,⁵ Christian Putensen,³ Michael T Heneka¹

- **Cognitive deficits :**
 - verbal learning
 - Short term memory
- **MRI :** significant reduction of hippocampal volume
- **EEG :** low-frequency activity indicating unspecific brain dysfunction

Brain dysfunction in sepsis

- Definitions
- Risk factors and outcomes
- **Is clinical evaluation feasible ?**
- Does EEG help ?
- Biomarkers ?
- When should we perform brain MRI ?
- Major confounders
- Conclusion

Ten false beliefs in neurocritical care


Geert Meyfroidt^{1,2*} , David Menon^{3,4,5,6,7} and Alexis F. Turgeon⁸

1. Clinical examination of neurocritically ill patients is impossible.




“Red flags”

- Poor motor response (GCS) : $M < 3$
- Focalization
- ICU-acquired seizure(s)
- Loss of brainstem reflex(es)
 - pupillary reflex
 - corneal reflex
 - cough
- Myoclonus



Validation of a New Coma Scale: The FOUR Score



FOUR Score

Eye response

- 4 = eyelids open or opened, tracking, or blinking to command
- 3 = eyelids open but not tracking
- 2 = eyelids closed but open to loud voice
- 1 = eyelids closed but open to pain
- 0 = eyelids remain closed with pain

Motor response

- 4 = thumbs-up, fist, or peace sign
- 3 = localizing to pain
- 2 = flexion response to pain
- 1 = extension response to pain
- 0 = no response to pain or generalized myoclonus status

Brainstem reflexes

- 4 = pupil and corneal reflexes present
- 3 = one pupil wide and fixed
- 2 = pupil or corneal reflexes absent
- 1 = pupil and corneal reflexes absent
- 0 = absent pupil, corneal, and cough reflex

Respiration

- 4 = not intubated, regular breathing pattern
- 3 = not intubated, Cheyne Stokes breathing pattern
- 2 = not intubated, irregular breathing
- 1 = breathes above ventilator rate
- 0 = breathes at ventilator rate or apnea

FOUR = Full Outline of UnResponsiveness.


The FOUR score provides **greater neurological detail** than the GCS, **recognizes a locked-in syndrome**, and is superior to the GCS due to the availability of **brainstem reflexes**, **breathing patterns**, and the ability to recognize different stages of **herniation**.



Early multimodal non-invasive monitoring

Clinical evaluation
(GCS, CAM-ICU...)

Biomarkers
(NSE, S100b)



EEG
Evoked
potentials

CT, MRI



Functional
outcome ?

Brain dysfunction in sepsis

- Definitions
- Risk factors and outcomes
- Is clinical evaluation feasible ?
- **Does EEG help ?**
- Biomarkers ?
- When should we perform brain MRI ?
- Major confounders
- Conclusion

Sepsis-associated encephalopathy

Jeanette E. Gordon and C. Bryan Young





Table 1 | Changes in EEG recordings in patients with SAE*

| Degree of encephalopathy | EEG findings (% of patients) | | | | |
|--------------------------|------------------------------|-------------|-------------|-----------------|---------------------------|
| | Normal | Theta waves | Delta waves | Triphasic waves | Burst-suppression pattern |
| None | 50 | 38 | 12 | 0 | 0 |
| Mild | 0 | 47 | 54 | 0 | 0 |
| Severe | 0 | 10 | 40 | 20 | 30 |


* Generated from data provided by Young *et al.*⁸⁶ Abbreviation: SAE, sepsis-associated encephalopathy.

Sepsis-associated encephalopathy

Jeanette E. Coffin and G. Bryan Young




EEG CHANGES AND OUTCOMES




Nat Review Neurol 2012
Young et al., J Clin Neurophysiol 1992

Early Standard Electroencephalogram Abnormalities Predict Mortality In Septic Intensive Care Unit Patients

Erik Andersson¹, Erik Maynard², Andre Brachmann³, Lars Ydstad⁴, Ugo Mayen⁵, Nicholas Henning⁶, Ojalil Arriaga⁷, Jean-Marie⁸, Tobias Christen⁹, Marie-Christine Darnet¹⁰, Robert Lofgren¹¹, Raphael Roubicek¹², Thibault Isenhardt¹³, A couple of European countries have accepted the Human Genome Project.



Reactivity




Reactivity -

RESEARCH ARTICLE


Early Standard Electroencephalogram Abnormalities Predict Mortality In Septic Intensive Care Unit Patients

Eric Padua^{1,2}, Eric Maghin², Anthony Brachonny², Lynn Yalowitz², Urs Messner², Nicholas Herlihy², Jill Lee Annand², Jean-Marie Fabrice Chretien², Marie-Christine Girard², Polina Lurion², Raphael Ponzio², Thomas Hirsch^{2,3,4}, & a group of European Neuroscience Centers (EUNEC) ¹INSERM U1152, ²INSERM U1152, ³INSERM U1152, ⁴INSERM U1152



Periodic discharges

Electric seizures



Early Standard Electroencephalogram Abnormalities Predict Mortality In Septic Intensive Care Unit Patients

Eric Padua^{1*}, Eric Magalhaes², Andreia Brachmann³, Lene Vollmar⁴, Urs Messer⁵, Nicholas Heming⁶, Gail Annane⁷, Jean-Marie Fabrice Chretien⁸, Marie-Christine Orban⁹, Robert Lofgren¹⁰, Raphael Ranzani¹¹, Thomas R. Piech¹², A. Sampaio¹³, J. P. de Souza¹⁴, M. A. de Souza¹⁵, M. A. de Souza¹⁶

Table 4. Adjusted analysis of the association of EEG findings with day 28 mortality.


| Variable | Adjusted on SAPS-II at admission and sedation | | | Adjusted on SOFA at EEG and sedation | | |
|-------------------------|---|----------------|-------|--------------------------------------|----------------|-------|
| | OR | (95%CI) | P | OR | (95%CI) | P |
| Delta-dominant activity | 3.36 | (1.08 to 10.4) | 0.036 | 3.08 | (0.93 to 10.2) | 0.066 |
| Absence of reactivity | 4.44 | (1.37 to 14.3) | 0.013 | 4.57 | (1.36 to 15.4) | 0.014 |
| Periodic Discharges | 3.24 | (1.03 to 10.2) | 0.044 | 3.31 | (0.98 to 11.2) | 0.054 |
| Synek's score ≥ 3 | 5.35 | (1.66 to 17.2) | 0.005 | 5.68 | (1.63 to 19.8) | 0.006 |
| Young's score > 1 | 3.44 | (1.09 to 10.8) | 0.035 | 3.43 | (1.02 to 11.5) | 0.045 |

Abbreviations: SAPS-II: New Simplified Acute Physiology Score; SOFA: Sepsis-related Organ Failure Assessment.

Emily J. Gilmore
Nicolas Gaspard
Huimahn A. Choi
Emily Cohen
Kristin M. Burkart
David H. Chong
Jan Claussen
Lawrence J. Hirsch

**Acute brain failure in severe sepsis:
a prospective study in the medical intensive
care unit utilizing continuous EEG monitoring**

100 septic episodes in 98 patients
Periodic discharges : 25%
Non convulsive seizures : 10%
Unreactive EEG background : 28%





Brain dysfunction in sepsis

- Definitions
- Risk factors and outcomes
- Is clinical evaluation feasible ?
- Does EEG help ?
- **Biomarkers ?**
- When should we perform brain MRI ?
- Major confounders
- Conclusion

Admission plasma levels of the neuronal injury marker neuron-specific enolase are associated with mortality and delirium in sepsis



Brian J. Anderson, MD, MS^{a,b,*}, John P. Reilly, MD, MS^a, Michael G.S. Shashaty, MD, MS^{a,b}, Jessica A. Palakshappa, MD^{a,h}, Alex Wysoczanski^a, Thomas G. Dunn, BA^a, Altaf Kazi, PhD^a, Anna Tommasini, BA^d, Mark E. Mikkelsen, MD, MS^{a,h}, William D. Schweickert, MD^d, Dennis L. Kolson, MD, PhD^c, Jason D. Christie, MD, MS^{a,b,i}, Nuala J. Meyer, MD, MS^{a,i}

Retrospective analysis of 124 patients from a large sepsis cohort.

Plasma NSE was measured in the earliest blood draw at intensive care unit admission.

Primary outcomes : 30-day mortality and ICU delirium (chart review)

SAE




Fig. 3. Adjusted probability of delirium according to plasma NSE concentration at ICU admission. Points represent the adjusted delirium risk, and vertical error bars represent 95% CIs. The NSE concentration is plotted on the log base 2 scale. After adjustment for APACHE III score and receipt of sedative and analgesic infusions, each 2-fold increase in the plasma NSE concentration was associated with a 5.2% increased risk of delirium ($P < .001$).

Mortality





Fig. 2. Adjusted probability of 30-day mortality according to the plasma NSE concentration at ICU admission. Points represent the adjusted mortality risk, and vertical error bars represent 95% CIs. The NSE concentration is plotted on the log base 2 scale. After adjustment for APACHE III score, admission location, age, and ARDS, each 2-fold increase in the plasma NSE concentration was associated with a 7.3% increased risk of 30-day mortality ($P = .003$).


Serum S100 β is a Better Biomarker than Neuron-Specific Enolase for Sepsis-Associated Encephalopathy and Determining Its Prognosis: A Prospective and Observational Study

Bo Yao · Li-Na Zhang · Yu-Hang Ai ·
Zhi-Yong Liu · Li Huang

SAE



Mortality






Brain dysfunction in sepsis

- Definitions
- Risk factors and outcomes
- Is clinical evaluation feasible ?
- Does EEG help ?
- Biomarkers ?
- **When should we perform brain MRI ?**
- Major confounders
- Conclusion

Pattern of Brain Injury in the Acute Setting of Human Septic Shock

N=71 septic shock patients underwent MRI because of encephalopathy, focal signs or seizures






72 yr-old patient
Streptococcus pneumoniae pneumonia, normal CSF examination
 Septic shock
 Persistent encephalopathy

Brain lesions in septic shock: a magnetic resonance imaging study





Acute brain MRI lesions : 130/146 (89 %) pts

- White matter lesions (104/146, 71 %)
- Acute cerebral infarcts (59/146, 40 %).

Acute brain MRI lesions **were independently associated with**

Brain dysfunction in sepsis

- Definitions
- Risk factors and outcomes
- Is clinical evaluation feasible ?
- Does EEG help ?
- Biomarkers ?
- When should we perform brain MRI ?
- **Major confounders**
- Conclusion

DAILY INTERRUPTION OF SEDATIVE INFUSIONS IN CRITICALLY ILL PATIENTS UNDERGOING MECHANICAL VENTILATION

JOHN P. KRESS, M.D., ANNE S. POHLMAN, R.N., MICHAEL F. O'CONNOR, M.D., AND JESSE B. HALL, M.D.




Figure 1. Kaplan-Meier Analysis of the Duration of Mechanical Ventilation, According to Study Group. After adjustment for base-line variables (age, sex, weight, APACHE II score, and type of respiratory failure), mechanical ventilation was discontinued earlier in the intervention group than in the control group (relative risk of extubation, 1.9; 95 percent confidence interval, 1.3 to 2.7; $P < 0.001$).

DAILY INTERRUPTION OF SEDATIVE INFUSIONS IN CRITICALLY ILL PATIENTS UNDERGOING MECHANICAL VENTILATION

JOHN P. KRESS, M.D., ANNE S. POHLMAN, R.N., MICHAEL F. O'CONNOR, M.D., AND JESSE B. HALL, M.D.

128 patients in MICU

Intervention: Interruption of sedative infusions until patients awake, on a daily basis

Control: the infusions were interrupted only at the discretion of the clinicians

| | Intervention (n=68) | Control (n=60) | p |
|--|--------------------------------|---------------------------|----------|
| Total dose of MDZ, mg | 230 (59–491) | 425 (208–824) | .05 |
| Total dose of morphine, mg | 205 (68–393) | 481 (239–748) | .009 |
| Median duration of MV, days | 4.9 | 7.3 | .004 |
| Median duration of ICU stay, days | 6.4 | 9.9 | .02 |
| Diagnostic testing to assess change in mental status, n (%) | 6 (9%) | 16 (27%) | .02 |
| Complications (e.g., self-extubation) | 3 (4%) | 4 (7%) | .88 |

Effect of Sedation With Dexmedetomidine vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients

The MENDS Randomized Controlled Trial

Table 2. Outcomes in Mechanically Ventilated Patients Sedated With Dexmedetomidine vs Lorazepam^a

| Outcome Variable | Dexmedetomidine (n = 52) | Lorazepam (n = 51) | P Value |
|---|--------------------------|--------------------|---------|
| Duration of brain organ dysfunction, d | | | |
| Delirium-free and coma-free ^b | 7 (1-10) | 3 (1-6) | .01 |
| Delirium-free ^b | 9 (5-11) | 7 (5-10) | .09 |
| Coma-free ^b | 10 (9-12) | 8 (5-10) | <.001 |
| Delirium | 2.5 (1-5) | 4 (1-5) | .71 |
| Coma | 2 (0-3) | 3 (2-5) | .003 |
| Prevalence of brain organ dysfunction, No. (%) ^c | | | |
| Delirium or coma | 45 (87) | 50 (98) | .03 |
| Delirium | 41 (79) | 42 (82) | .65 |
| Coma | 33 (63) | 47 (92) | <.001 |
| Other clinical outcomes | | | |
| Mechanical ventilator-free, d ^d | 22 (0-24) | 18 (0-23) | .22 |
| Intensive care unit length of stay, d | 7.5 (5-19) | 9 (6-15) | .92 |
| 28-Day mortality, No. (%) | 9 (17) | 14 (27) | .18 |


^aMedian (interquartile range) unless otherwise noted.

^bIndicates the number of days alive without stated dysfunction from study days 1 to 12.


^cPrevalence is used to describe the rates of brain organ dysfunction instead of incidence because preintensive care unit delirium or coma status could not be determined. Prevalence represents the occurrence of brain organ dysfunction at any time during the 12-day assessment period.

^dIndicates the number of days alive, breathing without mechanical ventilator assistance, from study day 1 to 28.

Figure 2. Delirium-Free and Coma-Free Days During Study



Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an *a priori*-designed analysis of the MENDS randomized controlled trial






Potentially modifiable factors contributing to sepsis-associated encephalopathy

Romain Sonnevile^{1,2}, Ltienne de Montmollin^{3,4}, Julien Roujade¹, Maïté Garrouste-Orgeas^{5,6}, Bertrand Souweine⁶, Michaël Darmon^{5,6}, Eric Mariotte⁷, Laurent Argaud¹⁰, François Barbier¹¹, Dany Gologran-Isledano¹², Guillaume Marcotte¹³, Anne Sylvie Dumenil¹⁴, Samir Jamal¹⁵, Guillaume Lacave¹⁶, Stéphane Ruckly², Bruno Mourvillat^{1,8} and Jean-François Timsit^{1,8}

Risk factors for sepsis-associated encephalopathy, multivariate analysis

| Variable | OR | 95% CI | | p value |
|-------------------------------------|------|--------|------|---------|
| Age, per 1-year increment | 1.02 | 1.01 | 1.02 | <0.01 |
| Chronic alcohol abuse | 3.38 | 2.34 | 4.89 | <0.01 |
| History of neurological disease | 1.56 | 1.18 | 2.06 | <0.01 |
| Pre-existing cognitive impairment | 2.25 | 1.09 | 4.67 | 0.03 |
| Long-term use of psychoactive drugs | 1.37 | 1.11 | 1.70 | <0.01 |
| Medical admission ^a | 1.75 | 1.43 | 2.14 | <0.01 |
| Renal SOFA > 2 | 1.41 | 1.19 | 1.67 | <0.01 |
| Hypoglycemia, <3 mmol/l | 2.66 | 1.27 | 5.59 | <0.01 |
| Hyperglycemia, >10 mmol/l | 1.37 | 1.09 | 1.72 | <0.01 |
| Hypercapnia, >45 mmHg | 1.91 | 1.53 | 2.38 | <0.01 |
| Hypernatremia, >145 mmol/l | 2.30 | 1.48 | 3.57 | <0.01 |





RESEARCH

Open Access

Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy

Jennifer E. Fugère¹, Jason A. Kellinick², Sara E. Koller¹, Sarah L. Clark³, Deko TM Wijetunge¹ and Alejandro A. Pastores^{1*}

Procedia (ed.) Intensive Care 2017, 17:10584
DOI: 10.1016/j.proci.2017.10.055-6

 **Annals of Intensive Care**

RESEARCH

Open Access

Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects



Mathilde Kervelleh^{1*}, Najoua E. Helal², Eric Magalhães¹, Ayoub Kadou¹, Roland Vroeg¹,
Jean François Seaburn³, Guillaume Wond¹, Alsaïd El Menem⁴, Stéphane Bocky⁵, Lili Bouadine^{1,6},
Benoît Somerville¹, Jean-Tyrone Tsim^{1,6} and Bruno Mouvillier^{1,6}

Brain dysfunction in sepsis

- Definitions
- Risk factors and outcomes
- Is clinical evaluation feasible ?
- Does EEG help ?
- Biomarkers ?
- When should we perform brain MRI ?
- Major confounders
- **Conclusion**

Conclusions

- **Neurological dysfunction** is observed in **50% of patients with sepsis**
- **Brain dysfunction** is a **strong predictor of poor outcome**
- **A Multimodal non invasive monitoring is feasible in septic patients**
 - Clinical examination with appropriate tools
 - EEG : background changes, reactivity
 - Brain MRI for selected patients : white matter abnormalities, ischemia
- **Evaluation of confounders is critical for appropriate neurological evaluation**
 - Renal failure and metabolic disturbances
 - Antibiotic neurotoxicity
 - Sedatives



PIC 2018

PARIS 21st-22nd JUNE

Update
in Neurocritical Care

www.srlf.org

VENUE:

THE HOUSE OF INTENSIVE CARE
48, avenue Claude Valéfaux 75010 Paris, France

Line 2: station "Colonel Fabien"
Line 11: station "Gare d'Orléans"

INFORMATIONS:

T: +33 (0)1 45 86 74 00
E: secretariat@uif.org

